Literature DB >> 7976637

Administration of an omega-conopeptide one hour following traumatic brain injury reduces 45calcium accumulation.

D A Hovda1, K Fu, H Badie, A Samii, P Pinanong, D P Becker.   

Abstract

The omega-conopeptide, SNX-111 (NEUREX Corporation) was administered to rats 1 hour following a lateral fluid percussion brain injury to determine if the drug could reduced the extent and duration of trauma-induced calcium accumulation. Administration at doses of 3 or 5 mg/kg (i.v.) markedly reduced the extent of calcium accumulation as determined using 45calcium autoradiography primarily within the cerebral cortex and hippocampus. The reduction of calcium accumulation was particularly event within the parietal cortex beginning as early as 6 hours and lasting out to 48 hours following injury. Although not as effective as in the cerebral cortex, SNX-111 did exhibit a reduction of calcium accumulation within the dorsal hippocampus especially at 24 and 48 hours after the insult. These preliminary results demonstrate that SNX-111 can reduce the injury-induced accumulation of calcium even when administered 1 hour after the insult and offers this compound as a potential therapeutic treatment for traumatic brain injury.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7976637     DOI: 10.1007/978-3-7091-9334-1_143

Source DB:  PubMed          Journal:  Acta Neurochir Suppl (Wien)


  9 in total

1.  Changes in volumetric and metabolic parameters relate to differences in exposure to sub-concussive head impacts.

Authors:  Allen A Champagne; Nicole S Coverdale; Mike Germuska; Alex A Bhogal; Douglas J Cook
Journal:  J Cereb Blood Flow Metab       Date:  2019-07-15       Impact factor: 6.200

2.  Omega-conotoxin MVIIC attenuates neuronal apoptosis in vitro and improves significant recovery after spinal cord injury in vivo in rats.

Authors:  Karen M Oliveira; Mário Sérgio L Lavor; Carla Maria O Silva; Fabíola B Fukushima; Isabel R Rosado; Juneo F Silva; Bernardo C Martins; Laís B Guimarães; Marcus Vinícius Gomez; Marília M Melo; Eliane G Melo
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Neuroprotective effects of selective N-type VGCC blockade on stretch-injury-induced calcium dynamics in cortical neurons.

Authors:  Kiarash Shahlaie; Bruce G Lyeth; Gene G Gurkoff; J Paul Muizelaar; Robert F Berman
Journal:  J Neurotrauma       Date:  2010-01       Impact factor: 5.269

4.  Exploring temporospatial changes in glucose metabolic disorder, learning, and memory dysfunction in a rat model of diffuse axonal injury.

Authors:  Jia Li; Lei Gu; Dong-Fu Feng; Fang Ding; Guangyao Zhu; Jiandong Rong
Journal:  J Neurotrauma       Date:  2012-11-20       Impact factor: 5.269

Review 5.  Emerging treatments for traumatic brain injury.

Authors:  Ye Xiong; Asim Mahmood; Michael Chopp
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

6.  Concussions: What a neurosurgeon should know about current scientific evidence and management strategies.

Authors:  Matthew T Neal; Jonathan L Wilson; Wesley Hsu; Alexander K Powers
Journal:  Surg Neurol Int       Date:  2012-02-15

Review 7.  Pathogenesis and management of traumatic brain injury (TBI): role of neuroinflammation and anti-inflammatory drugs.

Authors:  Sunishtha Kalra; Rohit Malik; Govind Singh; Saurabh Bhatia; Ahmed Al-Harrasi; Syam Mohan; Mohammed Albratty; Ali Albarrati; Murtaza M Tambuwala
Journal:  Inflammopharmacology       Date:  2022-07-08       Impact factor: 5.093

8.  Voltage-gated calcium channel antagonists and traumatic brain injury.

Authors:  Gene Gurkoff; Kiarash Shahlaie; Bruce Lyeth; Robert Berman
Journal:  Pharmaceuticals (Basel)       Date:  2013-06-26

9.  Conotoxin MVIIA improves cell viability and antioxidant system after spinal cord injury in rats.

Authors:  Karen M Oliveira; Nancy S Binda; Mário Sérgio L Lavor; Carla M O Silva; Isabel R Rosado; Endrigo L A Gabellini; Juliana F Da Silva; Camila M Oliveira; Marília M Melo; Marcus Vinícius Gomez; Eliane G Melo
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.